Alpine Immune Sciences Inc.

Entering 2025, biopharma industry observers expected an uptick of merger-and-acquisition activity, coming off a 2024 that saw some historic lows for such activity. Hopes were raised with some sizeab

The past year yielded a downward trend across the board for dealmaking in the biopharmaceutical sector, regardless of which metric one looks at. In the area of mergers and acquisitions, deal volume, t

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

In Vivo’s editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2024. Vote now in the polls belo